Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

As global markets navigate a muted response to new U.S. tariffs and mixed economic signals, the Asian tech sector remains a focal point for investors seeking high growth opportunities. With market ...

On May 6, Arcutis reported first-quarter results showed loss of 20 cents a share, which slightly beat estimates. Its sales ...

Stocks like Wipro, Axis Bank, LTIMindtree, Indian Hotels, Lupin, Tracxn Technologies, Capital Small Finance Bank, Veranda ...

The U.S. stock market has been navigating a wave of uncertainty, with recent tariff threats from President Trump causing fluctuations across major indices such as the Dow Jones, S&P 500, and Nasdaq.

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...

Glenmark stock surged over 10 per cent, hitting a fresh 52‑week high at Rs 1,905 following its biggest-ever licensing ...

Their first product, Illuccix, is a diagnostic imaging agent that allows PET scanners to light up the prostate cancer cells ...

The new space is a free community service meant to help healthcare entrepreneurs connect with potential funders.

Investment management company Vulcan Value Partners recently released its second-quarter 2025 investor letter. A copy of the ...

Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.